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Abstract
Background: Schizophrenia (SCZ) is associated with increased risk of type 2 diabetes (T2D). The potential diabetogenic
effect of concomitant application of psychotropic treatment classes in patients with SCZ has not yet been evaluated. The
overarching goal of the Genetic Overlap between Metabolic and Psychiatric disease (GOMAP) study is to assess the effect
of pharmacological, anthropometric, lifestyle and clinical measurements, helping elucidate the mechanisms underlying
the aetiology of T2D.
Methods: The GOMAP case-control study (Genetic Overlap between Metabolic and Psychiatric disease) includes
hospitalized patients with SCZ, some of whom have T2D. We enrolled 1653 patients with SCZ; 611 with T2D and
1042 patients without T2D. This is the first study of SCZ and T2D comorbidity at this scale in the Greek population. We
retrieved detailed information on first- and second-generation antipsychotics (FGA, SGA), antidepressants and mood
stabilizers, applied as monotherapy, 2-drug combination, or as 3- or more drug combination. We assessed the effects of
psychotropic medication, body mass index, duration of schizophrenia, number of hospitalizations and physical activity
on risk of T2D. Using logistic regression, we calculated crude and adjusted odds ratios (OR) to identify associations
between demographic factors and the psychiatric medications.
Results: Patients with SCZ on a combination of at least three different classes of psychiatric drugs had a higher risk of
T2D [OR 1.81 (95% CI 1.22–2.69); p = 0.003] compared to FGA alone therapy, after adjustment for age, BMI, sex, duration
of SCZ and number of hospitalizations. We did not find evidence for an association of SGA use or the combination of
drugs belonging to two different classes of psychiatric medications with increased risk of T2D [1.27 (0.84–1.93), p = 0.259
and 0.98 (0.71–1.35), p = 0.885, respectively] compared to FGA use.
Conclusions: We find an increased risk of T2D in patients with SCZ who take a combination of at least three different
psychotropic medication classes compared to patients whose medication consists only of one or two classes of drugs.
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Background
Schizophrenia (SCZ) is associated with increased risk of
obesity, impaired glucose tolerance, and type 2 diabetes
(T2D) [1]. The prevalence of T2D among patients with
SCZ in European populations is estimated to be up to
22.0% [2–6]. No information is available on T2D preva-
lence among psychiatric disease patients in Greece,
whereas the current prevalence of T2D in the general
Greek population has been estimated to be 11.97% (men
13.98%, women 9.25%), clearly indicating a major public
health problem [7]. T2D is a major risk factor for cardio-
vascular disease and the fourth highest cause of excess
mortality in patients with SCZ [8], leading to signifi-
cantly shorter life expectancy [9]. Antipsychotic-naïve
individuals with a first-episode SCZ often present with
elevated fasting plasma glucose, impaired oral glucose
tolerance and fasting plasma insulin levels, as well as in-
sulin resistance, possibly owing to shared disease path-
ways [10]. Further factors possibly associated with the
increased risk of T2D amongst patients with SCZ in-
clude ethnicity, obesity, a sedentary lifestyle, smoking,
unhealthy dietary habits, hypertension, hyperlipidemia,
social determinants of health, genetics, as well as
long-term treatment with psychotropic drugs.
In order to investigate the epidemiological and genetic
associations with cardiometabolic disease in patients
with psychiatric disorders we established the GOMAP
study (Genetic Overlap between Metabolic and Psychi-
atric disease), a new hospital-based collection of patients
with psychiatric disease, with and without T2D. Com-
monly prescribed drugs include SGA, FGA, antidepres-
sants, and mood stabilizers. These can be applied as
monotherapy, 2-drug combination, or as 3- or more
drug combinations in SCZ patients. A small number of
studies have evaluated the potential diabetogenic effect
of specific psychotropic drug classes.
Antidepressants and mood stabilizers have been indi-
vidually associated with T2D risk. Associations between
antidepressants [11–17], such as amitriptyline and mir-
tazapine, mood stabilizers [16, 18], such as lithium and
valproate, modest weight gain and T2D have been re-
ported, although the literature is still inconclusive [19].
A 9-year longitudinal study of the Data from an Epi-
demiological Study on the Insulin Resistance Syndrome
(D.E.S.I.R. cohort) reported that the association between
antidepressants use and diabetes might not be causal
[20]. However, a recent meta-analysis indicated that anti-
depressants increase the likelihood of new-onset T2D
[21]. A further cohort study conducted between 2005
and 2015 including 2579 SCZ patients revealed an inde-
pendent association between antidepressants and risk of
T2D for SCZ patients [9]. Furthermore, mood stabilizers
have been found to be associated with an elevated risk
for the development of insulin resistance in patients with
epilepsy [22] or depression [23], whereas no association
was found in patients with severe mental illness, with
the exception of lithium [17]. Two studies have evalu-
ated the effects of co-prescribed medications on T2D
risk and both focused on youths exposed to limited
medication regiments [24–26]. One of these studies [25]
found a higher risk of T2D in patients receiving SGA to-
gether with antidepressants compared with patients re-
ceiving SGA only or antidepressants only.
A better understanding of the underlying mechanism
linking T2D and psychiatric disorders can provide evi-
dence and help shape strategies for the prevention of
T2D in this group of patients. Here, we have studied risk
factors linking pharmacological treatment and the risk
of T2D in patients with SCZ.
Methods
Study population
GOMAP is a nested case-control study. Participants were
recruited from two hospitals in Athens, Greece (Dromokai-
teio Psychiatric Hospital and Dafni Psychiatric Hospital).
Briefly, in the work presented here, we randomly selected
and screened 5985 patients. We excluded in total 4332 pa-
tients (Fig. 1) based on the following exclusion criteria: 1)
age < 18 years, 2) presence of a psychiatric disorder other
than SCZ, 3) presence of type 1 diabetes, latent auto-
immune diabetes of adults, or gestational diabetes, 4) in-
ability to provide informed consent due to mental state
following consultation with the treating psychiatrist, 5)
pregnancy or breastfeeding, and 6) non-Greek ancestry.
Ethical approval was obtained from the regulatory
bodies of the participating hospitals. All study partici-
pants gave written informed consent following a detailed
explanation of the study. This work has been carried out
in accordance with the latest version of the Declaration
of Helsinki [27].
Medication data collection
The medication data sources used in the study include
medical records from the hospital where the participant
enrollment took place, as well as the database of the elec-
tronic prescription platform of the National Organization
for Health Care Services Provision for the medication his-
tory. When gaps were detected in terms of treatment in-
formation accuracy, or in treatment compliance certainty,
candidates were excluded. After careful quality checks of
the medication data, the participants selected for inclusion
had received one of the following four non-overlapping
treatment categories consistently for a duration of at least
six months: 1) monotherapy with FGA antipsychotics, 2)
monotherapy with SGA antipsychotics, 3) combined ther-
apy of two psychiatric medications, one of which anti-
psychotic and the second other class antipsychotic,
antidepressant or mood stabilizer, and 4) triple or more
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psychiatric medications, one of which antipsychotic the
other as in group before. Individuals switched to an-
other treatment category were excluded from the study,
however candidates switched to another regimen of the
same category or additionally receiving another regi-
men of same category remained in the study. Recur-
rence of schizophrenia during this six months period
was handled with application of parenteral aloperidin
and benzodiazepine for no longer that 3 days, according
to hospital’s protocol, a procedure that is not associated
with T2D risk and was homogenously applied to all pa-
tients requiring it.
Study procedure
The fieldwork was carried out between January 2012 and
May 2014 and included an interview, a questionnaire
concerning lifestyle habits, detailed medical history,
treatment information, anthropometric measurements as
well as a venous blood draw. Weight, height, waist and
hip circumference were recorded for all individuals, and
BMI and waist-to-hip ratio were calculated. Further-
more, syndrome profiles of the SCZ subjects were evalu-
ated by performing the 30-item rating the Positive and
Negative Syndrome Scale PANSS questionnaire, as
adapted and validated for the Greek population [28].
Patients had received a diagnosis of SCZ, based on the
structured clinical interview of the Diagnostic and Statis-
tical Manual of Mental Disorders, (DSM-IV-TR) [29].
The diagnostic assessment of T2D was determined as
defined by the American Diabetes Association [30]. Fur-
ther, all individuals were asked to participate in an ex-
tensive screening of metabolic parameters.
Statistical analysis
Comparisons between categorical and continuous vari-
ables were performed through a t-test. Nonparametric
Mann-Whitney and Kruskal-Wallis tests were used due
to the skewed distributions of some variables. Differ-
ences in proportions for outcome variables between
groups were compared using Pearson’s chi-squared or
Fisher’s exact test where appropriate. Multivariable logis-
tic analyses were performed to examine associations be-
tween clinical important variables (sex, duration of SCZ,
number of hospitalizations, psychiatric medication) and
T2D status. Age and BMI were systematically introduced
in the logistic model (adjusted results). The Benjamini
and Hochberg procedure was used to correct for mul-
tiple testing [31]. Nominal statistical significance was set
at p < 0.05. The analyses were performed using R (R ver-
sion 3.2.2; The R Foundation for Statistical Computing,
Vienna, Austria).
Genotype analysis
A total of 1519 DNA samples from the GOMAP cohort
(977 with SCZ, 542 with SCZ and T2D) were genotyped
on the Illumina HumanCoreExome (Illumina, San Diego)
Fig. 1 Study participant flow diagram. SCZ: schizophrenia, BD: bipolar disorder, MDD: major depressive disorder, T2D: type 2 diabetes
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chip. Following standard quality control procedures [32],
we retained 1429 samples genotyped at 524271 markers.
We imputed GOMAP together with two in-house Greek
sample collections, ARGO and TEENAGE, using a
merged reference panel of UK10K, 1000 Genomes Project
and MANOLIS [33] (a Greek isolated population) haplo-
types using the IMPUTEv2 software [34]. After filtering
for Hardy-Weinberg equilibrium (p < 1 × 10− 4), IMPUTE
v2 info score (info< 0.4) and minor allele frequency < 1%,
there were 9,565,382 genetic variants in the dataset. We
performed a GWAS on T2D status in the group of pa-
tients receiving a combination of three or more drugs
(ncases = 94, ncontrols = 121), two of which had to be of the
SGA or FGA class. We adjusted for the first 10 compo-
nents derived from multidimensional scaling (MDS) of
GOMAP together with TEENAGE [35] and ARGO. The
power of this comparison is very low, but the data are
available through the European Genome/Phenome Arch-
ive (EGA) for potential future meta-analyses.
Results
The clinical and demographic characteristics of partici-
pants are displayed in Table 1, and treatment regimens are
presented in Table 2. Of the 1653 participants with SCZ
included in our analysis, 611 (36.96%) also had T2D. Our
study achieved a collection of 3.2–5.9% of the entire Greek
T2D and SCZ comorbid population, calculated according
to the T2D general Greek population prevalence and to
the European SCZ and T2D comorbidity prevalence,
respectively. The whole sample included 672 women
(40.7%) and 981 men (59.3%) with mean age 50.22 years
(SD 14.03) and mean BMI 27.58 kg/m2 (SD 5.77).
We considered four non-overlapping treatment cat-
egories: those receiving monotherapy with FGA antipsy-
chotics (n = 373), those receiving monotherapy with
SGA antipsychotics (n = 215), those under combined
therapy of two psychiatric medications, one of which
antipsychotic (n = 570), and those under triple or more
psychiatric medications, one of which antipsychotic (n =
232). Consistent with the literature, our study confirms
that obesity [36, 37] and increasing age [38, 39] repre-
sent independent risk factors for T2D in patients with
SCZ (Additional file 1: Table S1). Adjusting for age and
BMI (Table 3, column 1) the results indicated that sex
(p = 0.063), SGA (p = 0.595), 2-drug combination (p =
0.937), duration of SCZ (p = 0.960), number of hospitali-
sations (p = 0.937) and outdoor physical activity in last
week (p = 0.858), were not significantly associated with
risk of T2D. However, the combined use of at least three
psychotropic drugs was associated with higher risk of
T2D (p = 0.035) compared with FGA monotherapy.
Furthermore, in multivariable logistic regression ana-
lysis that included adjustment for age, BMI, sex, dur-
ation of SCZ and number of hospitalizations, the
combination use of at least three psychotropic medica-
tions [odds ratio (OR), 95% confidence intervals (CI)]
[1.81 (1.22–2.69), p = 0.003] was significantly associated
with higher risk of T2D (Table 3).
Table 1 Characteristics of 1390 SCZ patients with T2D (n = 536) and without T2D (n = 854)
Characteristics SCZ without T2D
n = 854 (61.44%)
SCZ with T2D
n = 536 (38.56%)
Corrected
p value****
Mean (SD)*
Age (years) 45.83 (12.98) 57.07 (12.25) < 0.0001
SCZ duration (years) 18.57 (11.69) 26.30 (11.61) < 0.0001
BMI (kg/m2) 25.97 (4.54) 30.56 (6.75) < 0.0001
n (%)**
Male 516 (60.42%) 310 (57.84%) 0.467
Female 338 (39.58%) 226 (42.16%)
Number of subjects who reported outdoor
physical activity in last week
16 (1.87%) 4 (0.75%) 0.172
Number of subjects who reported no outdoor
physical activity in last week
838 (98.13%) 532 (99.25%)
Median (IQR)***
Number of Hospitalizations 4.00 (3.00–7.00) 3.00 (2.00–6.00) < 0.0001
Positive Symptoms 31.00 (27.00–36.00) 32.00 (27.00–37.00) 0.532
Negative Symptoms 30.00 (26.50–34.00) 30.00 (25.00–34.00) 0.486
General Psychopathology Scale 55.00 (48.00–64.00) 54.00 (47.00–64.00) 0.179
PANSS total score 118.00 (105.00–130.50) 117.00 (103.00–131.00) 0.467
SD: standard deviation; IQR: interquartile range
*t-test, **x2 test, ***Wilcoxon Rank Sum test, ****Corrected p-value using Benjamini and Hochberg method for the comparison between SCZ patients with and
without T2D
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We examined the genetic relationship between psy-
chotropic medication and T2D risk in the subset of indi-
viduals who were on a polypharmacy medication
regimen in the GOMAP cohort. No significant findings
were observed, likely due to small sample size and low
power (Additional file 1: Figure S1 and S2).
Discussion
We have established a novel case-control sample collec-
tion (GOMAP) with extensive phenotyping to examine
clinical epidemiological factors that may increase the
risk of T2D in patients with SCZ. We identify a previ-
ously unreported association between T2D and the con-
comitant prescription of three or more different
psychotropic medication classes, including at least one
antipsychotic, when compared to FGA monotherapy.
We do not identify SGA as a significant risk factor com-
pared to FGA, despite high power to detect moderate ef-
fects (86% power to detect an OR of 2). Both FGA and
SGA have been previously linked to an increased risk of
T2D [40–43]. While some studies suggest that SGA use is
associated with a higher risk of T2D development com-
pared to FGA use [24, 44], others were inconclusive [42].
One possible explanation is that there is no difference in
diabetogenic effect between SGA and FGA [45]. A recent
meta-analysis [17] demonstrated that individual FGA and
SGA drugs were associated with higher T2D risk, but did
not find a significant difference in T2D risk between drugs
of these classes. In addition, a systematic review of 22 ran-
domized control trials detected no difference in glycemic
effect of antipsychotics versus placebo [46].
It is also possible that we did not detect a difference in
T2D risk between SGA and FGA use because of varying
diabetogenic profiles among the individual drugs within
these classes [47–49]. There is conflicting evidence for dif-
ferential diabetogenic effects of antipsychotics of the same
class [50]. For example [51], the SGA aripiprazole has
been associated with decreased T2D risk in first-episode
patients with SCZ, while olanzapine (SGA), low-potency
FGAs and clozapine (SGA) have all been found to increase
T2D risk [51]. Conversely, the SGA risperidone has been
shown to confer a similar diabetogenic risk to FGAs [52].
A further study found no statistically significant differ-
ences in fasting glucose between patients receiving FGA
and SGA when patients treated with clozapine and olan-
zapine were excluded [53]. Further, the inconsistency of
these findings in the literature could be partly due to un-
measured confounding factors [54], such as genetic back-
ground. For example, the Australian National Survey of
Psychosis has shown that antipsychotic treatment had no
Table 2 Psychiatric medication
SCZ without T2D SCZ with T2D
Monotherapy
FGA 246 (17.7%) 127 (9.14%)
SGA 126 (9.06%) 89 (6.40%)
Combination Therapy
2-Drug Combination (Antipsychotic + 1 more psychiatric medication) 361 (25.97%) 209 (15.04%)
≥3-Drug Combination (Antipsychotic + 2 or more psychiatric medications) 121 (8.71%) 111 (7.99%)
FGA first generation antipsychotics, SGA second generation antipsychotics
Table 3 Crude and adjusted odds ratios (OR) of T2D occurrence based on logistic regression modelling among patients with SCZ
Variables Crudea Adjustedc
OR (95%CI) Corrected p-value OR (95%CI) p-value
Sex
(Reference group = Female)
1.38 (1.06–1.81) 0.063 1.42 (1.08–1.85)a 0.0112
Psychiatric Medication
(Reference group = FGA)
SGA 1.27 (0.84–1.93) 0.595 1.27 (0.84–1.93) 0.259
2-Drug Combination 0.96 (0.69–1.33) 0.937 0.98 (0.71–1.35) 0.885
≥3-Drug Combination 1.75 (1.19–2.59)b 0.035 1.81 (1.22–2.69)b 0.003
Number of hospitalizations 1.00 (0.96–1.03) 0.937 0.99 (0.96–1.03) 0.749
Duration of SCZ 1.00 (0.98–1.02) 0.960 1.00 (0.98–1.02) 0.975
Outdoor Physical activity in last week: (reference group = No) 0.62 (0.16–2.38) 0.858 0.71 (0.19–2.66) 0.613
aadjusted for age and BMI
bSignificant predictor of T2D among SCZ patients
cAdjusted for age, BMI, sex, duration of SCZ and number of hospitalizations
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additional impact on T2D risk in those with a T2D family
history, whereas antipsychotics increased T2D risk in
those without a T2D family history [39].
A recent meta-analysis of studies on comorbid SCZ with
T2D in China showed that duration of schizophrenia (>
10 years) is a significant risk factor for T2D development
[55]. We observed similar statistically significant results,
but no association when we dichotomized SCZ duration
into less or more than 10 years (OR 1.46, 95% CI: 0.89–
2.4). We do not identify association between PANSS psy-
chopathology scores, examined separately for positive
symptoms, negative symptoms and the total score with
T2D risk. A single study has shown an inverse relationship
between PANSS score and BMI in SCZ patients, but con-
tains no information on T2D prevalence [56]. Moreover,
we do not find an association between physical activity
and T2D in SCZ; this may be due to the effect of
hospitalization, which results in a largely uniform environ-
ment in terms of physical activity and nutrition.
Many combinations of different classes of medications
were used for the management of SCZ in our sample;
this does not allow us to perform robust sub-analysis to
examine the diabetogenic effect of different classes of
medications, because of the small number of patients in
each category. Importantly, we identify a significant risk
attributable to the potential diabetogenic effect of psy-
chotropic combinations, which are frequently applied in
SCZ treatment, though we attempted no such associ-
ation analysis for antidepressants or mood stabilizers ap-
plied as monotherapy given our small sample size in
these groups respectively. To date, most studies have
not extensively considered other medication variables or
their combinations. Similarly, a recent study [25] on
youths identified a higher risk of T2D in patients receiv-
ing SGA together with antidepressants compared with
patients receiving only SGA or only antidepressants.
Moreover, no difference in T2D occurrence was detected
between receiving stimulants concomitantly to SGA, as
compared with SGA only. There is further acknowledge-
ment that the increase in T2D risk in SGA-exposed
youths remains small. Both studies emphasize the im-
portance of including all psychotropic regimens received
by SCZ patients when analyzing T2D risk to avoid miss-
ing synergy in this direction. Our study demonstrates
the effect of combined psychiatric medication on T2D
risk. Given the widespread use of combined categories of
psychiatric medications, we suggest future studies should
prospectively explore the effect of different treatment
options on type 2 diabetes incidences, in order to formu-
late clinical guidelines.
A limitation of our study is that we only had access to
retrospective medication information of up to six months
prior to study commencement. This means that metabolic
adverse effects of drugs beyond that period could not be
accounted for and we cannot evaluate the effect of previous
treatment regimens on T2D risk. Further we cannot make
inferences about T2D causality, medication dose-effect,
additional medication categories effect, differences in medi-
cation effects when patients are drug-naïve, or experience
first SCZ episode; nor how effective, in terms of T2D
prophylaxis, switching from one medication category to an-
other might be. Additional factors that should be consid-
ered in a study of the metabolic effects of antipsychotic
medications are duration of treatment [51, 57] and body
weight before treatment initiation. Due to limited sample
size it was not possible to study the effect of specific psy-
chotropic medications, or various combinations thereof.
However, this study has examined a relatively large
number of hospitalized participants, who have been care-
fully selected and ascertained for T2D and SCZ diagnoses
based on established criteria rather than self-reporting.
The homogeneity in the ethnicity of the studied popula-
tion limits the potential for ancestry bias. Furthermore,
our study is estimated to have collected 3.2–5.9% of the
entire Greek T2D and SCZ comorbid population. We
were further able to assess the effect of psychotropic medi-
cation in the context of SCZ alone, rather than having to
account for several different psychiatric diagnoses [58].
Adherence to treatment was strictly inspected.
While the genetic analysis did not yield any robust sig-
nals, it might prove useful in downstream meta-analyses.
The genotype data used here have been made available
through the European Genome/Phenome Archive.
Conclusions
Our findings indicate that a triple-drug combination ther-
apy for patients with SCZ is associated with increased risk
of T2D compared with treatment involving FGA. Future
studies should explore the research hypothesis that
maximization of monotherapy doses or switch to a differ-
ent antipsychotic class may be associated with decreased
diabetogenic effect as compared with the addition of mul-
tiple antipsychotic medications.
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of association results from a GWAS on T2D in individuals receiving a
combination of three or more psychotropic drugs, including one FGA
and one SGA. For each SNP the –log10 of the p-value is plotted against
its expected value under the null distribution. (DOCX 219 kb)
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